纳米载体靶向输送miRNAs反义核酸用于子痫前期治疗的实验研究
结题报告
批准号:
81971409
项目类别:
面上项目
资助金额:
53.0 万元
负责人:
李磊
依托单位:
学科分类:
妊娠相关性疾病
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
李磊
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
PE严重威害母儿安全,治疗中存在尖锐的母胎利益冲突,EVT侵袭力下降是该病发生的关键环节,具体分子机制不清。研究证实,miRNAs可通过靶基因调控EVT功能,在PE发生发展中发挥作用。但绝大多数miRNAs的功能和调控机制尚不清楚。申请人研究发现,PE胎盘中miR-513c-5p表达上调,LRP6表达下调;又证实,EVT中miR-513c-5p可靶向抑制LRP6表达,而LRP6表达下调可致EVT功能受损。项目拟进一步验证miR-513c-5p对LRP6的靶向调控作用,阐明其与EVT侵袭力下降和PE发病的关系。项目还将尝试构建纳米载体plCSA-LPH-NPs,靶向输送miR-513c-5p反义核酸进入EVT,下调miR-513c-5p,上调LRP6表达,改善EVT功能,治疗PE。将为进一步认识PE发病机制提供新的理论依据,为核酸药物、纳米载体等技术方法在PE靶向治疗领域的应用提供实践基础。
英文摘要
Preeclampsia (PE) is a serious pregnant complication, and there are sharp conflicts of interest between mother and fetus in the treatment. Its specific molecular mechanism is unclear, and declined invasion of extravillous trophoblast (EVT) is a key point. MiRNAs can regulate EVT function through their target genes, and play an important role in the development of PE. However, the functions and regulatory mechanisms of most miRNAs are still unclear. Our preliminary study found that the expression of mir-513c-5p was up-regulated, while the expression of LRP6 was down-regulated in the PE placentas. And it was confirmed in EVT that mir-513c-5p can targeted inhibit the expression of LRP6, while the down-regulation of LRP6 can lead to the impairment of EVT function. The project intends to further verify the targeted regulatory effects of mir-513c-5p on LRP6, and clarify their relationship with the decline of EVT invasiveness and the development of PE. The project will also attempt to construct plCSA-LPH-NPs nanoparticular (NP) system to deliver mir-513c-5p antisense oligonucleotide (ASO) into EVT, down-regulate mir-513c-5p, up-regulate LRP6 expression, improve EVT function and treat PE. We wish the results can provide a new theoretical basis for further understanding the pathogenesis of PE, and provide a practical basis for the application of nucleic acid drugs, NPs and other technical methods in the field of PE targeted therapy.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.3389/fcvm.2022.1061340
发表时间:2022
期刊:Frontiers in cardiovascular medicine
影响因子:3.6
作者:Gu M;Zhang F;Jiang X;Chen P;Wan S;Lv Q;Lu Y;Zhou Q;Wang Y;Li L
通讯作者:Li L
DOI:10.3389/fcell.2022.889861
发表时间:2022
期刊:FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
影响因子:5.5
作者:Wan, Shuting;Chen, Pengzheng;Gu, Mengqi;Liu, Jing;Zhou, Qian;Zhang, Fengyuan;Lu, Yuan;Li, Lei;Wang, Xietong
通讯作者:Wang, Xietong
DOI:10.1007/s12079-023-00751-0
发表时间:2023-05
期刊:Journal of Cell Communication and Signaling
影响因子:4.1
作者:Xiao Gu;Xiaomei Sun;Yanling Yu;Lei Li
通讯作者:Xiao Gu;Xiaomei Sun;Yanling Yu;Lei Li
DOI:10.1186/s12964-023-01286-y
发表时间:2023-11-23
期刊:CELL COMMUNICATION AND SIGNALING
影响因子:8.4
作者:Gu, Mengqi;Chen, Pengzheng;Zeng, Dongmei;Jiang, Xiaotong;Lv, Qingfeng;Li, Yuchen;Zhang, Fengyuan;Wan, Shuting;Zhou, Qian;Lu, Yuan;Wang, Xietong;Li, Lei
通讯作者:Li, Lei
面向增减材复合制造的高效轻量化液压集成块优化设计方法
  • 批准号:
    --
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2022
  • 负责人:
    李磊
  • 依托单位:
基于磺酰类单体的点击聚合
  • 批准号:
    21901144
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    25.0万元
  • 批准年份:
    2019
  • 负责人:
    李磊
  • 依托单位:
国内基金
海外基金